中国经济网北京10月7日讯 铭利达(301268.SZ)2025年半年度报告显示，公司上半年实现营业收入 15.26亿元，同比增长37.95%；归属于上市公司股东的净利润-0.32亿元，上年同期为-0.97亿元；归属于 上市公司股东的扣除非经常性损益的净利润-0.45亿元，上年同期为-1.04亿元；经营活动产生的现金流 量净额-1.88亿元，上年同期为-2.52亿元。 铭利达首次公开发行新股募集资金总额为11.40亿元，募集资金净额为10.42亿元。该公司最终募集 资金净额比原计划多2.61亿元。2022年3月31日，铭利达披露的招股书显示，公司拟募集资金7.81亿元， 分别用于轻量化铝镁合金精密结构件及塑胶件智能制造项目、研发中心建设项目、补充流动资金。 铭利达发行费用总额（不含增值税）为9830.52万元，国泰君安证券股份有限公司获得保荐及承销 费用6954.98万元。 2023年8月21日，铭利达发布的向不特定对象发行可转换公司债券上市公告书显示，本次发行数量 为100,000.00万元（1,000.00万张），发行价格为100元/张，可转换公司债券的面值为人民币100元。本 次发行的募集资金总额为人民 ...

中国经济网北京9月17日讯泽璟制药(688266.SH)2025年半年度报告显示，2025年上半年，公司实现营业收 入3.76亿元，同比增长56.07%；归属于上市公司股东的净利润-7280.35万元；归属于上市公司股东的扣除 非经常性损益的净利润-1.03亿元；经营活动产生的现金流量净额-1702.03万元。 泽璟制药首次公开发行股票募集资金总额为202,560.00万元，募集资金净额为190,822.08万元。该公司最 终募集资金净额较原计划少47565.92万元。泽璟制药于2020年1月20日发布的招股书显示，其拟募集资金 238,388万元，分别用于新药研发项目、新药研发生产中心二期工程建设项目、营运及发展储备资金。 泽璟制药首次公开发行股票的发行费用(不含税)总额为11,737.92万元，其中中国国际金融股份有限公司、 东吴证券股份有限公司获得保荐和承销费10,328.00万元。 根据泽璟制药于2023年4月25日发布的向特定对象发行股票上市公告书，2023年4月17日，经信永中和会 计师事务所(特殊普通合伙)出具的《苏州泽璟生物制药股份有限公司验资报告》 (XYZH/2023NJAA1B0108) ...

中国经济网北京7月30日讯 君实生物(688180.SH)今日收报39.12元，跌幅4.59%。 君实生物于2020年7月15日在上交所科创板上市，发行数量为8713万股，发行价格为55.50元/股，保荐 机构、主承销商为中国国际金融股份有限公司，联席主承销商为国泰君安证券股份有限公司、海通证券 股份有限公司（2家公司现已合并为国泰海通证券股份有限公司）。 上市首日，君实生物股价最高报220.40元，此后该股一路震荡下滑，目前该股处于破发状态。 君实生物首发募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多 17.97亿元。君实生物2020年7月8日发布的招股说明书显示，公司计划募集资金27.00亿元，分别用于创 新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资金。 君实生物上市发行费用为3.39亿元，其中保荐机构中金公司（601995）及联席主承销商国泰海通证券股 份有限公司获得保荐及承销费用3.20亿元，容诚会计师事务所（特殊普通合伙）获得审计、评估及验资 费用590.00万元，北京市嘉源律师事务所获得律师费用616.50万元。 君实生物2022年度向 ...

Core Viewpoint - The announcement details a share reduction plan by Yuan Liping, a significant shareholder of Kangtai Biological, which will not affect the company's control or governance structure [1][3]. Shareholder Changes - Yuan Liping plans to reduce her holdings by up to 11,160,000 shares, representing 1.00% of the total share capital, within three months from the announcement date [1]. - As of July 24, 2025, Yuan Liping has already reduced her holdings by 4,307,904 shares, which is 0.38% of the total share capital, realizing approximately 74.35 million yuan [1]. - Prior to this reduction, Yuan Liping held 137,331,675 shares (19.61% of total capital), and after the reduction, she holds 197,422,776 shares (17.68% of total capital) [1]. Control and Governance - The reduction in shares will not lead to a change in the company's control or significantly impact its governance structure [3]. - Before the reduction, Yuan Liping and other associated parties held a combined total of 339,099,830 shares (48.42% of total capital), which decreased to 530,121,967 shares (47.46% of total capital) after the reduction [2]. Fundraising Activities - Kangtai Biological raised a total of 3 billion yuan through a private placement of shares in 2020, with a net amount of approximately 2.985 billion yuan after expenses [3]. - In 2021, the company issued 20 million convertible bonds, raising a total of 2 billion yuan, with a net amount of approximately 1.98966 billion yuan after expenses [4]. - Over the past five years, Kangtai Biological has cumulatively raised 5 billion yuan [5].

Group 1 - The controlling shareholder's action person, Gao Lei, plans to reduce his shareholding by up to 6,779,157 shares, accounting for 3.00% of the total share capital after excluding shares in the repurchase account, due to personal funding needs [1] - As of December 31, 2024, the controlling shareholders, Lü Jiezhong, Lü Baozhong, and Gao Lei, collectively hold 72,714,025 shares, representing 45.10% of the total share capital [1] - The company was listed on the Shenzhen Stock Exchange's ChiNext board on January 27, 2021, raising a total of 607 million yuan, with a net amount of 539 million yuan after deducting issuance costs [2] Group 2 - The company issued convertible bonds on November 9, 2023, raising a total of 545 million yuan, with net proceeds of approximately 538.36 million yuan after deducting underwriting fees [3] - The total amount raised from the two fundraising activities amounts to 1.152 billion yuan [4]

Core Viewpoint - The actual controller and several executives of Haigang Co., Ltd. plan to reduce their shareholdings due to personal financial needs, with a total reduction not exceeding 3% of the company's total share capital [1][5]. Shareholding Summary - Qian Liping, one of the actual controllers, holds a total of 10,540,838 shares (10.1004% of total share capital) and plans to reduce her holdings by up to 3,120,000 shares (2.9896%) within three months starting from 15 trading days after the announcement [1][2]. - The total shareholding of the actual controllers and their concerted actions amounts to 32,939,000 shares (31.5626% of total share capital) [2]. Reduction Plans of Executives - Executive Qian Xiaoda plans to reduce his indirect holdings by up to 45,000 shares (0.0431%) [3][7]. - Financial Director Li Jian plans to reduce his indirect holdings by up to 39,000 shares (0.0374%) [3][7]. - Vice General Manager Zhao Yubao plans to reduce his indirect holdings by up to 44,000 shares (0.0422%) [4][7]. - Vice General Manager Li Xin and Chairman of the Supervisory Board Jiang Wei each plan to reduce their indirect holdings by up to 40,000 shares (0.0383%) [4][7]. Financial Background - The shares being reduced were acquired before the company's initial public offering [5]. - As of March 31, 2025, Qian Liping is the fourth largest shareholder with 7,454,438 shares (7.14% of total share capital) [8]. - The company has not experienced a situation of breaking the net asset value or share price, and its cumulative cash dividends over the past three years have not been less than 30% of the average annual net profit [7].

Group 1 - The core point of the news is that Yunnan Daye Shengde Enterprise Management Co., Ltd. plans to reduce its holdings in Keda Li (002850.SZ) by up to 3,824,933 shares, which represents 1.3985% of the company's total share capital, without causing a change in actual control [1] - Keda Li's major shareholders, Li Jili and Li Jianju, will continue to hold 102,163,386 shares, accounting for 37.3532% of the total share capital after the reduction [1] - Keda Li was listed on March 2, 2017, with an initial issuance price of 37.70 yuan per share, raising a total of 1,319.50 million yuan [1] Group 2 - The company was approved to issue up to 40 million shares through a private placement, ultimately issuing 22,920,451 shares at an issuance price of 60.47 yuan per share, raising approximately 1,385.99 million yuan [2] - After deducting underwriting and other fees, the net proceeds from this issuance amounted to approximately 1,360.36 million yuan [2] - The company issued 15,343,705 convertible bonds with a total fundraising amount of 1,534.37 million yuan, with net proceeds of approximately 1,515.10 million yuan after deducting fees [3] Group 3 - The company received approval to issue 33,471,626 shares to specific investors, raising a total of approximately 3,509.50 million yuan, with net proceeds of about 3,480.12 million yuan after deducting issuance costs [4] - The total amount raised by Keda Li through four fundraising activities is approximately 774.94 million yuan [5]

Core Viewpoint - The share reduction plan by major shareholders of Yirui Biological has been completed, resulting in a total cash-out of approximately 8.83 million yuan from the sales of shares [1][2]. Shareholder Reduction Summary - Yirui Biological's major shareholders, Yidari and Yikairei, executed their share reduction plans, with Yidari reducing 411,200 shares (0.1025% of total shares) and Yikairei reducing 575,700 shares (0.1435% of total shares) [1][3]. - Yidari's share reduction occurred through concentrated bidding and block trading, with an average price of 9.33 yuan per share for 116,200 shares and 8.76 yuan per share for 295,000 shares [3]. - Yikairei's share reduction also involved concentrated bidding and block trading, with an average price of 9.30 yuan per share for 275,700 shares and 8.66 yuan per share for 300,000 shares [3]. Shareholder Equity Changes - Shareholder Wang Tianyi reduced his holdings by 6,337,700 shares (1.5792% of total shares) from April 25 to June 6, 2025, bringing his total holdings down to 20,065,821 shares (4.999984% of total shares) [2][4]. - Wang Tianyi's reduction means he is no longer a major shareholder with over 5% ownership [2][4]. Company Financial Activities - Yirui Biological raised a total of 217 million yuan during its IPO, with a net amount of 175 million yuan after deducting issuance costs [6]. - The company issued convertible bonds worth 328.2 million yuan in August 2023, which began trading on September 6, 2023 [7].

Summary of Key Points Core Viewpoint - 康泰医学's controlling shareholder, 胡坤, plans to reduce his stake in the company by up to 12 million shares, which is approximately 2.99% of the total share capital, through both centralized bidding and block trading methods [1] Group 1: Shareholder Reduction Plan - 胡坤 currently holds 188,189,252 shares, representing 46.84% of the total share capital [1] - The reduction will occur within three months starting from fifteen trading days after the announcement [1] - The reduction includes a maximum of 4 million shares through centralized bidding and 8 million shares through block trading [1] Group 2: Financial Performance - In 2024, 康泰医学 reported a revenue of 480 million yuan, a decrease of 35.76% compared to 2023 [4][5] - The net profit attributable to shareholders was -77.9 million yuan, a decline of 147% from the previous year [4][5] - The net cash flow from operating activities was 62.34 million yuan, down 65.56% year-on-year [4][5] Group 3: Fundraising Activities - 康泰医学 has raised a total of 1.117 billion yuan since its listing, including 4.17 billion yuan from its initial public offering [2][3] - The company issued 7 million convertible bonds in 2022, raising 700 million yuan, with a net amount of approximately 688 million yuan after expenses [3]